JAMA· 2015Q1

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

Jeffrey G. Gross, Adam R. Glassman, Lee M. Jampol, Seidu Inusah et al.

766citations
Q1SCImago
2015year

Short summary

Intravitreous ranibizumab achieved non-inferior visual acuity compared to panretinal photocoagulation (PRP) over 2 years in patients with proliferative diabetic retinopathy, with significantly less peripheral vision loss, vitrectomy, and diabetic macular edema (DME).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Ophthalmology

OphthalmologyMedicine